|
Session 104
Poster Abstracts
ART: Randomized Trials
Monday, 1-2:30 pm
Poster Hall |
| 571a |
Weekly and Biweekly Subcutaneous PRO 140 Demonstrates Potent, Sustained Antiviral Activity
Melanie Thompson*1, J Lalezari2, M Saag2, J Jacobson3, B Zingman4, N Stambler5, P D'Ambrosio5, P Maddon5, W Olson5, and S Morris5
1AIDS Res Consortium of Atlanta, GA, US; 2Quest Clinical Res, San Francisco, CA, US; 3Drexel Univ Coll of Med, Philadelphia, PA, US; 4Montefiore Med Ctr, Bronx, NY, US; and 5Progenics Pharmaceuticals, Tarrytown, NY, US |
571b
 |
96-Week Results from BENCHMRK 1 and 2, Phase III Studies of Raltegravir in Patients Failing ART with Triple-class-resistant HIV
Roy Steigbigel*1, D Cooper2, J Eron3, J Gatell4, P Kumar5, J Rockstroh6, H Wan7, P Sklar7, H Teppler7, B-Y Nguyen7, and BENCHMRK-1 and 2 Study Groups
1State Univ of New York at Stony Brook, US; 2Univ of New South Wales, Sydney, Australia; 3Univ of North Carolina at Chapel Hill, US; 4Univ of Barcelona, Spain; 5Georgetown Univ Med Ctr, Washington, DC, US; 6Univ of Bonn, Germany; and 7Merck Res Labs, West Point, PA, US |
572
|
Switch from Enfuvirtide to Raltegravir in Highly Treatment-experienced HIV-1-infected Patients: A Randomized Open-label Non-inferiority Trial, Easier--ANRS 138
Nathalie De Castro*1, J Braun2, I Charreau2, G Pialoux3, L Cotte4, C Katlama5, C Delaugerre1, I Madelaine-Chambrin1, J-P Aboulker2, J-M Molina1, and the ANRS 138 Study Group
1St Louis Hosp, Paris, France; 2INSERM SC10, Villejuif, France; 3Hosp Tenon, Paris, France; 4Hotel Dieu Hosp., Lyon, France; and 5Hosp Pitie-Salpetriere, Paris, France |
573
|
Subgroup Analyses from STARTMRK, a Phase III Study of Raltegravir-based vs Efavirenz-based Combination Therapy in Treatment-naïve HIV-infected Patients
Jeffrey Lennox*1, E Dejesus2, A Lazzarin3, R Pollard4, J Madruga5, J Zhao6, A Rodgers6, B-Y Nguyen6, R Leavitt6, and P Sklar6
1Emory Univ, Atlanta, GA, US; 2Orlando Immunology Ctr, FL, US; 3University Vita-Salute San Raffaele, Milan, Italy; 4Univ of California, Davis, US; 5Centro de Referencia e Treinamento DST/AIDS, Sao Paulo, Brazil; and 6Merck Res Labs, North Wales, PA, US |
574
|
Immune Activation Markers during Raltegravir Intensification of a HAART Regimen in Subjects with Persistent HIV-1 Viral Suppression
Marta Massanella Luna*1, J Llibre2, M Larrousse3, P Domingo4, N Pérez-Alvarez2,5, C Caum2, B Clotet1,2, and J Blanco1
1IrsiCaixa Foundation, Germans Trias i Pujol University Hospital, Badalona, Spain; 2Lluita contra la SIDA Foundation, Germans Trias i Pujol University Hospital, Badalona, Spain; 3Servicio de enfermedades infecciosas. Hospital Clínic i Provincial de Barcelona, Spain; 4Servicio de enfermedades infecciosas, Hospital de la Santa Creu i Sant Pau. Barcelona, Spain; and 5Statistics and Operations Research Department, Technical University of Catalonia, Barcelona, Spain |
575
|
Factors Affecting Virologic Response to Darunavir/Ritonavir and Lopinavir/Ritonavir in Treatment-naïve HIV Patients: ARTEMIS at 96 Weeks
M Nelson1, P Yeni2, Michael Sension*3, P Ive4, L Chen5, A Hill6, R Demasi5, and S Spinosa-Guzman7
1Chelsea and Westminster Hosp, London, UK; 2Hôpital Bichat and University of Paris, Paris, France; 3Comprehensive Care Ctr, Fort Lauderdale, FL, US; 4Univ of the Witwatersrand, Johannesburg, South Africa; 5Tibotec, Yardley, PA, US; 6Univ of Liverpool, UK; and 7Tibotec BVBA, Mechelen, Belgiuim |
576
|
Simplification with Fixed-dose Tenofovir/Emtricitabine or Abacavir/Lamivudine in Adults with Suppressed HIV Replication: The STEAL Study, a Randomized, Open-label, 96-Week, Non-inferiority Trial
D Cooper1, M Bloch2, A Humphries1, J Amin1, D Baker3, S Emery1, Andrew Carr*4, and for the STEAL Study Investigators
1Natl Ctr in HIV Epi and Clinical Res, Univ of New South Wales, Sydney, Australia; 2Holdsworth House Gen Practice, Sydney, Australia; 3East Sydney Doctors, Australia; and 4St Vincent`s Hosp, Sydney, Australia |
| 577 |
High-dose Atorvastatin Decreases Cellular Immune Activation Markers without Affecting HIV-I RNA levels: Results of a Randomized, Placebo-controlled Clinical Trial
Anuradha Ganesan*1,2, N Crum-Cianflone1,3, J Qin4, S McCarthy1,2, C Brandt1,3, R McConnell4, C Rehm4, K Gittens1,2, S Tasker2, and F Maldarelli5
1Infectious Disease Clinical Res Prgm, Uniformed Svcs Univ of the Hlth Sci, Bethesda, MD, US; 2Natl Naval Med Ctr, Bethesda, MD, US; 3Naval Med Ctr, San Diego, CA, US; 4NIAID, NIH, Bethesda, MD, US; and 5HIV Drug Resistance Prgm, NCI, Frederick, MD, US |
578
|
Low-nadir CD4 Count Predicts Failure of Monotherapy Maintenance with Ritonavir-boosted Lopinavir: Results after Premature Termination of a Randomized Study Due to Unexpectedly High Failure Rate in the Monotherapy Arm
C Gutmann1, M Opravil2, S Yerly3, C Fux4, H Furrer4, M Cavassini5, L-A Decosterd5, Bernard Hirschel*3, P Vernazza1, and the Swiss HIV Cohort Study
1Kantonsspital St Gallen, Switzerland; 2Univ Hosp Zurich, Switzerland; 3Univ Hosp Geneva, Switzerland; 4Univ Hosp Bern, Switzerland; and 5Univ Hosp Lausanne, Switzerland |
| 579 |
Waning of Virological Benefits following Directly Administered ART among Drug Users: Results from a Randomized, Controlled Trial
D Smith-Rohrberg Maru, R Bruce, M Walton, S Springer, and Frederick Altice*
AIDS Prgm, Yale Univ Sch of Med, New Haven, CT, US |
| 580 |
Virologic Failure Endpoint Definition in Clinical Trials: Is Using HIV-1 RNA Threshold <200 Copies/mL Better than <50 Copies/mL? An Analysis of ACTG Studies
Heather Ribaudo*1, J Lennox2, J Currier3, D Kuritzkes4, R Gulick5, R Haubrich6, S Riddler7, and M Hughes1
1Harvard Sch of Publ Hlth, Boston, MA, US; 2Emory Univ Sch of Med, Atlanta, GA, US; 3Univ of California, Los Angeles CARE Ctr, US; 4Brigham and Women`s Hosp, Boston, MA, US; 5Weill Med Coll of Cornell Univ, New York, NY, US; 6Univ of California, San Diego, US; and 7Univ of Pittsburgh, PA, US |
581
|
Safety and Efficacy of Autologous CD34+ Hematopoietic Progenitor Cells Transduced with Retroviral Vector Containing a Ribozyme Directed against the HIV-1 tat Gene, OZ1, in a Multicenter, Randomized, Placebo-controlled Phase II Trial
Ronald Mitsuyasu*1, T Merigan2, A Carr3, M Law4, J Murray4, J MacPherson5, G Symonds5, L Evans5, S Pond5, and D Cooper4
1Univ of California, Los Angeles, US; 2Stanford Univ, CA, US; 3St Vincent`s Hosp, Sydney, Australia; 4Univ of New South Wales, Sydney, Australia; and 5Johnson & Johnson Res Pty Ltd, Sydney, Australia |
|
